Financial News

Financial Report: Johnson & Johnson

Negative currency, Hep C hit impacts results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 3Q Revenues: $17.1 billion (-7%) 3Q Earnings: $3.4 billion (-29%) YTD Revenue: $52.3 billion (-7%) YTD Earnings: $12.2 billion (-12%) Comments: Worldwide Pharmaceutical sales were $7.7 billion in the quarter, down 7%, with a negative currency impact of 7%. Remicade sales were $1.6 billion in the quarter, down 10%. Sales of Hep C drug OLYSIO/SOVRIAD sunk 90% to $79 million due to competitive entrants (namely Gilead’s Harvoni). Stelara sales were $613 million, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters